

**BIOLIDICS LIMITED**  
(Company Registration No.: 200913076M)  
(Incorporated in the Republic of Singapore)  
(the “**Company**”)

---

**ACQUISITION OF THE ENTIRE ISSUED AND PAID-UP ORDINARY SHARES IN THE CAPITAL OF BIOMEDICS LABORATORY PTE. LTD.**

**- ENTRY INTO DEED OF ASSIGNMENT IN RELATION TO THE SALE AND PURCHASE AGREEMENT AND THE DEED OF SHARE CHARGE DATED 27 MARCH 2020 AND THE DEEDS OF AMENDMENT DATED 24 DECEMBER 2021, 24 JUNE 2022 AND 23 SEPTEMBER 2022**

---

**1. INTRODUCTION**

- 1.1. The board of directors (the “**Board**”) of Biolidics Limited (the “**Company**”, and together with its subsidiaries, collectively the “**Group**”) refers to the Company’s announcement dated 27 March 2020, circular to shareholders dated 8 April 2020 (“**Circular**”) and announcements dated 24 December 2021, 24 June 2022 and 23 September 2022 (“**Announcements**”) in relation to the acquisition (the “**Acquisition**”) of the entire issued and paid-up ordinary shares in the capital of Biomedics Laboratory Pte. Ltd. (the “**Target**”) from SAM Laboratory Pte. Ltd. (the “**Vendor**”).
- 1.2. All capitalised terms used and not defined in this announcement shall have the same meanings ascribed to them in the Circular and the Announcements.

**2. ENTRY INTO OF ASSIGNMENT DEED**

- 2.1. The Board wishes to announce that the Company, the Vendor and Clearbridge BSA Pte. Ltd. (“**CBSA**”), had on 29 September 2022, entered into a deed of assignment (the “**Assignment Deed**”) in relation to the SPA, the Share Charge, the First Amendment Deed, the Second Amendment Deed and the Third Amendment Deed (collectively, the “**Transaction Documents**”).
- 2.2. As at the date of this announcement, both the Vendor and CBSA are wholly-owned subsidiaries of Clearbridge Health Limited and CBSA is a controlling shareholder of the Company, holding 60,135,400 issued ordinary shares in the capital of the Company (“**Shares**”), representing approximately 22.65% of the total issued Shares.
- 2.3. Pursuant to the terms and conditions of the Assignment Deed and with effect on and from the date of the Assignment Deed:
  - (a) the Vendor assigns absolutely and without recourse to CBSA all of its rights, title and interests (whether present or future) and any and all rights, benefits, remedies and powers accrued and to accrue to the Vendor under (i) the Transaction Documents (including but not limited to the right to receive the Remaining Deferred Consideration and the right to enforce the Share Charge); and (ii) the proceeds of any payments which may at any time be received by or payable to the Vendor under or in connection with the Transaction Documents; and
  - (b) CBSA will have the benefit of the Transaction Documents and all rights, title and interests arising from the Transaction Documents (including any rights against third parties),

(the “**Assignment**”), and

the Company irrevocably acknowledges and consents to the Assignment.

3. **INTERESTS OF DIRECTORS AND CONTROLLING SHAREHOLDERS**

Save as disclosed in the Circular and in this announcement, none of the directors or controlling shareholders of the Company has any interest, direct or indirect, in the Assignment Deed, other than through their respective shareholdings (if any) in the Company.

4. **DOCUMENTS AVAILABLE FOR INSPECTION**

A copy of each of the Transaction Documents and the Assignment Deed will be made available for inspection during normal business hours at the registered office of the Company at 37 Jalan Pemimpin, #02-07 Mapex, Singapore 577177 for a period of three (3) months from the date of this announcement.

5. **CAUTIONARY STATEMENT**

Shareholders and potential investors are advised to exercise caution when trading in the Shares. In the event of any doubt as to the action they should take, Shareholders should consult their stock brokers, bank managers, solicitors or other professional advisors.

**BY ORDER OF THE BOARD**

**Song Tang Yih**  
**Executive Director and Chief Executive Officer**  
**29 September 2022**

*This announcement has been prepared by the Company and has been reviewed by the Company's sponsor, United Overseas Bank Limited (the "**Sponsor**"), for compliance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited ("**SGX-ST**") Listing Manual Section B: Rules of Catalist. This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Mr. Lim Hoon Khat, Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.*